Picture [LSUS] – The Business Web Portal 600x60px
Document › Details

Berlin Institute of Health. (10/4/17). "Press Release: BIH, Charité and MDC Sign Cooperation Agreement with Sanofi in Germany".

Region Region Germany
Organisations Organisation Berlin Institute of Health (BIH, Berliner Institut für Gesundheitsforschung)
  Group Humboldt University Berlin
  Organisation 2 Sanofi-Aventis Deutschland GmbH
  Group Sanofi (Group) [since May 2011]
Products Product drug development
  Product 2 translational medicine / translational research
Persons Person Zettl, Rolf (Helmholtz 201502 Managing Director)
  Person 2 Maas, Jochen (Sanofi 201505 Managing Director RnD at Sanofi Germany)

Research and development partnership to accelerate the development of novel therapies

The BIH, the Charité – Universitätsmedizin Berlin, the Max Delbrück Center for Molecular Medicine in the Helmholtz Association(MDC) and Sanofi, Germany GmbH signed a joint research framework agreement in Berlin on October 4, 2017. In the future, the institutions will work together closely on the development of novel therapies for various diseases. In addition, the partners will support talented young researchers and projects with economic and medical potential.

“We are pleased to extend the existing collaboration between Charité and Sanofi in Germany to BIH and MDC with the new contract. By bundling the competencies of all partners, we expect faster progress in development," said Dr. Rolf Zettl, Administrative Director at the BIH and responsible for Berlin Health Innovations, the joint technology transfer unit of BIH and Charité, at the signing ceremony. “The aim is to ensure that research findings reach patients quickly.”

“The framework agreement with these excellent research institutions is a very important milestone for our German research and development hub leading to a sustainable collaboration with global Sanofi research groups,” said Professor Jochen Maas, General Manager R&D Germany at Sanofi.

Over the next three years, the partners will jointly define scientific challenges and work together in projects extending to early research phases with collaborations beginning in the laboratory. This will enable researchers to identify the development and market potential of research projects more quickly and help promote and accelerate their development.

First joint activities focus on autoimmune diseases and current research activities of Charité and MDC. The partners will evaluate project ideas and pursue joint further development.


Dr. Klaus Nitschke
Director Berlin Health Innovations (interim)

Bernd Jablonka
Strategy & Business Development, Public-Private-Partnerships Sanofi in Germany

Record changed: 2017-10-16


Picture [LSA] – The Business Web Portal 650x89px

More documents for Humboldt University Berlin

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture EBD Group BIO-Europe 2019 Partnering Report BEU2019 650x80px

» top